Septerna, Inc. (NASDAQ:SEPN – Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as $4.17 and last traded at $6.87, with a volume of 8617193 shares. The stock had previously closed at $12.96.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on SEPN. TD Cowen initiated coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $50.00 price target on shares of Septerna in a research note on Tuesday, February 11th. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $43.00 to $14.00 in a research report on Tuesday. Finally, JPMorgan Chase & Co. initiated coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock.
Septerna Stock Performance
Institutional Trading of Septerna
Several hedge funds have recently made changes to their positions in SEPN. RA Capital Management L.P. purchased a new stake in shares of Septerna in the fourth quarter valued at $160,205,000. TRV GP V LLC purchased a new stake in Septerna in the 4th quarter worth about $142,337,000. TRV GP VI LLC bought a new stake in Septerna in the fourth quarter worth about $72,191,000. Samsara BioCapital LLC purchased a new position in shares of Septerna during the fourth quarter valued at approximately $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Septerna during the fourth quarter valued at approximately $59,301,000.
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
- Five stocks we like better than Septerna
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- Investing in the High PE Growth Stocks
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Growth Stocks: What They Are, Examples and How to Invest
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
